Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.

This abstract does not provide any specific results or findings but describes male androgenic alopecia as a progressive and psychologically distressing hair-loss disorder involving hair follicle miniaturization.

This study presents the first report on cloning and characterizing the full-length cDNA of SRD5A1 in Indian catfish (Clarias magur), revealing expression differences across reproductive phases and increased expression post-Ovatide administration in ovaries and testis.

This review analyzed the use of 5-alpha reductase inhibitors (5ARIs) for treating various dermatological conditions such as androgenetic alopecia, acne, and hirsutism, emphasizing their efficacy and safety profile.

This research highlights that while minoxidil and 5-alpha reductase inhibitors are commonly used for treating pattern hair loss, there is limited evidence supporting their relative effectiveness in women compared to men.

This study found that Eclipta alba extracts exhibit 5α-reductase inhibitory activity, with the methanolic extract showing a higher concentration of β-sitosterol compared to petroleum ether extract, indicating potential for treating androgenic conditions like male pattern baldness.

In this study, 30 patients with alopecia areata received intralesional methotrexate injections, resulting in significant hair regrowth and decreased levels of lesional TNF-α after three months, suggesting its effectiveness as a treatment.

This study examined lawsuits in Canada involving 5α-reductase inhibitors, revealing that all cases related to persistent erectile dysfunction as a side effect in men treated for hair loss, but no judgments have been made yet against physicians or pharmaceutical companies.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

In this case study, a woman with high 25(OH)D levels and persistent symptoms showed decreased parathormone after transdermal estrogen therapy, highlighting the importance of assessing both parathormone and estrogen levels in similar patients.

This narrative review discusses adverse effects associated with 5-ARI treatments for male-pattern baldness and benign prostate hyperplasia, including sexual health, neurological, endocrine, metabolic, and cardiovascular impacts, and emphasizes careful prescription assessment.

This hypothesis paper suggests that sexual and cognitive dysfunctions reported by some men after using finasteride and dutasteride may stem from vascular and tissue changes in penile tissue triggering broader inflammatory effects.

This review discusses frontal fibrosing alopecia and reports no new clinical results; the authors highlight the need for randomized controlled trials on 5AR inhibitors to assess their efficacy and safety.

This review discusses the potential of phytochemicals from plants as alternative treatments for prostate cancer, highlighting their possible benefits over current 5-alpha-Reductase inhibitors, but reports no new findings.

This review explores plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, for their potential use as alternative treatments for prostate cancer, emphasizing their effects on 5-alpha-Reductase enzyme isozymes. It reports no new clinical results.

This study found that the total testosterone/dihydrotestosterone ratio is significantly higher in women with polycystic ovary syndrome and is associated with a worse metabolic profile in both PCOS and healthy women.

This article describes the use, action, and considerations for 5-alpha-reductase inhibitors in treating benign prostatic hyperplasia and androgenic alopecia but provides no new clinical results, emphasizing existing knowledge and guidelines for healthcare providers.

This study found that finasteride treatment may decrease contraction of seminal vesicle tissue and alter some semen parameters in male rabbits.

After the FDA's 2011 warning about a potential prostate cancer risk with 5-alpha reductase inhibitors, this study observed a significant decrease in their prescriptions, notably a 49% drop among men with benign prostatic hyperplasia, while primary care providers reduced prescriptions by 60%.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This study found that dutasteride use was associated with a stable decrease in sexual function over four years, with no additional risk based on age or prostate size.

This review provides an up-to-date analysis of the efficacy and safety of five-alpha reductase inhibitors, specifically finasteride and dutasteride, for treating benign prostatic hyperplasia and male androgenetic alopecia, highlighting their FDA approval history and current use.

This study investigated the effects of 5-alpha-reductase inhibitors on penile histomorphometry in both normotensive and hypertensive rats, reporting no significant changes between treated and untreated groups.

This study reported that peginterferon alpha-2a showed high early and sustained virologic response rates in Albanian hemodialyzed patients with hepatitis C, despite causing several adverse effects.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

This study used machine learning to develop classifiers for identifying effective inhibitors of 5α-reductase isozyme 2, achieving high performance in distinguishing potent from weak inhibitors.

This consensus summary suggests that 5-alpha reductase inhibitors have clear benefits for benign prostatic hyperplasia, but their impact on prostate cancer prevention is still debated.

Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.

Some drugs for inflammation may cause psoriasis-like hair loss.

In this study, men using Propecia for alopecia showed normal erectile hemodynamics despite erectile dysfunction after stopping 5-alpha reductase inhibitors, while some BPH patients exhibited abnormal results potentially linked to vascular risk factors.